Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plitidepsin + sorafenib
- Development stage
- Unknown
- Lead developer
- PharmaMar
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Plitidepsin + sorafenib is an investigational combination therapy composed of two distinct anticancer agents. Plitidepsin is a cyclic depsipeptide originally isolated from the sea squirt Aplidium albicans and now produced synthetically. Its primary mechanism involves inhibition of eukaryotic translation elongation factor 1 alpha 2 (eEF1A2), leading to cell cycle arrest, induction of oxidative stress, and apoptosis in tumor cells. Sorafenib is a small molecule multikinase inhibitor that targets several kinases involved in tumor cell proliferation and angiogenesis, including RAF kinases and vascular endothelial growth factor receptor (VEGFR). Sorafenib is approved for advanced renal cell carcinoma, hepatocellular carcinoma not amenable to surgery, and certain types of thyroid cancer. The combination has been studied in early-phase clinical trials for advanced solid tumors or lymphomas[3][4][5].
- Brand names
- Nexavar
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)RAF1 (c-Raf-1 (Y340D/Y341D))EEF1A2 (Eukaryotic elongation factor 1 alpha 2)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on plitidepsin + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plitidepsin + sorafenib.